Literature DB >> 7986124

Treatment of epidermal pigmented lesions with the frequency-doubled Q-switched Nd:YAG laser. A controlled, single-impact, dose-response, multicenter trial.

S L Kilmer1, R G Wheeland, D J Goldberg, R R Anderson.   

Abstract

BACKGROUND AND
DESIGN: The removal of benign, aesthetically important, pigmented lesions can be effectively treated with multiple modalities. Selective removal of the pigment by lasers is becoming increasingly popular. A three-center trial evaluated the effectiveness of the frequency-doubled Q-switched neodymium (Nd):YAG laser (532 nm, 2.0-mm spot size, 10 nanoseconds) in removing benign epidermal pigmented lesions with a single treatment. Forty-nine patients were treated for multiple lentigines (n = 37), for cafe au lait macules (n = 7), and for miscellaneous lesions (n = 5). Treatment areas were divided into four quadrants, irradiated with fluences of 2, 3, 4, or 5 J/cm2 and evaluated at 1- and 3-month intervals following treatment.
RESULTS: For lentigines, response was related to dose with a greater than 75% pigment removal achieved in 60% of those lesions treated at higher energy fluences. Responses were more variable with other lesions, with fair-to-good improvement noted in most cases. Mild, transient erythema; hypopigmentation; and hyperpigmentation were noted in several patients, but resolved spontaneously within 3 months. No other textural changes, scarring, or other side effects were noted.
CONCLUSION: The frequency-doubled Q-switched Nd: YAG laser (532 nm) safely and effectively treats benign epidermal pigmented lesions.

Entities:  

Mesh:

Year:  1994        PMID: 7986124

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  11 in total

Review 1.  [Lasers and aesthetic dermatology].

Authors:  A J Stratigos; J S Dover; K A Arndt
Journal:  Hautarzt       Date:  2003-06-12       Impact factor: 0.751

2.  Comparison of short-pulsed and long-pulsed 532 nm lasers in the removal of freckles.

Authors:  Voraphol Vejjabhinanta; Mohamed L Elsaie; Shalu S Patel; Asha Patel; Caroline Caperton; Keyvan Nouri
Journal:  Lasers Med Sci       Date:  2010-06-26       Impact factor: 3.161

3.  New combined laser therapy for small mass of melanocytic nevi on the face.

Authors:  Youkou Ohmaru; Koichi Ohmaru; Noriyuki Koga; Hisashi Migita; Kensuke Kiyokawa
Journal:  Laser Ther       Date:  2011

4.  Solar Lentigines: Evaluating Pulsed Dye Laser (PDL) as an Effective Treatment Option.

Authors:  Hayedeh Ghaninejhadi; Amirhooshang Ehsani; Ladan Edrisi; Fatemeh Gholamali; Zahra Akbari; Pedram Noormohammadpour
Journal:  J Lasers Med Sci       Date:  2013

5.  A split-face, evaluator-blind randomized study on the early effects of Q-switched Nd:YAG laser plus Er:YAG micropeel (combined therapy) versus Q-switched Nd:YAG alone in light solar lentigines in Asians.

Authors:  Hee Jin Jun; Sang Hyun Cho; Jeong Deuk Lee; Hei Sung Kim
Journal:  Lasers Med Sci       Date:  2013-11-29       Impact factor: 3.161

6.  Response to Laser Treatment of Café au Lait Macules Based on Morphologic Features.

Authors:  Daniel A Belkin; Julia P Neckman; Hana Jeon; Paul Friedman; Roy G Geronemus
Journal:  JAMA Dermatol       Date:  2017-11-01       Impact factor: 10.282

7.  Treatment of Freckles Using a Fractional Nonablative 2940nm Erb:YAG Laser in a Series of Asian Patients.

Authors:  Brian Tian
Journal:  J Clin Aesthet Dermatol       Date:  2017-08-01

Review 8.  The role of lasers and intense pulsed light technology in dermatology.

Authors:  Zain Husain; Tina S Alster
Journal:  Clin Cosmet Investig Dermatol       Date:  2016-02-04

9.  Novel Low Fluence Combination Laser Treatment of Solar Lentigines in Type III Asian Skin.

Authors:  Brian Wei Cheng Anthony Tian
Journal:  J Cutan Aesthet Surg       Date:  2015 Oct-Dec

10.  Efficacy and safety of short-pulse erbium: Yttrium aluminum garnet laser treatment of Becker's nevus in Saudi patients: A pilot study.

Authors:  Fahad Al-Saif; E Al-Mekhadab; H Al-Saif
Journal:  Int J Health Sci (Qassim)       Date:  2017 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.